Lucentis and Neovascularisation - a phase IV clinical study of FDA data

Summary:

Neovascularisation is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Avastin, and have Age-related macular degeneration.

The phase IV clinical study analyzes which people have Neovascularisation when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Neovascularisation?

Neovascularisation (development of tiny, abnormal, leaky blood vessels inside the eye) is found to be associated with 64 drugs and 87 conditions by eHealthMe. Check the latest studies of Neovascularisation.

On Jul, 14, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 25 people (0.1%) have Neovascularisation.

Could Lucentis cause Neovascularisation?

Among these 25 people:

How long have people been on Lucentis when they have Neovascularisation? *

What is the gender of people who have Neovascularisation when taking Lucentis? *

female: 20 %
male: 80 %

What is the age of people who have Neovascularisation when taking Lucentis? *

What are other drugs people take besides Lucentis? *

What are other side effects people have besides Neovascularisation? *

Visual Acuity Reduced (reduced clearness of vision): 11 people, 44.00%
Cataract (clouding of the lens inside the eye): 7 people, 28.00%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 7 people, 28.00%
Visual Impairment: 6 people, 24.00%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 5 people, 20.00%
Retinal Degeneration (death of the cells of the retina): 4 people, 16.00%
Vision Blurred: 4 people, 16.00%
Retinal Oedema (swelling of retina): 4 people, 16.00%
Drug Ineffective: 3 people, 12.00%
Disease Progression: 3 people, 12.00%

What are the existing conditions these people have? *

Age-Related Macular Degeneration: 10 people, 40.00%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 4 people, 16.00%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 4 people, 16.00%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 2 people, 8.00%
Diabetes: 2 people, 8.00%
Visual Impairment: 1 person, 4.00%
Venous Occlusion (the blocking of venous return): 1 person, 4.00%
Type 2 Diabetes: 1 person, 4.00%
Retinopathy (acute damage to the retina of the eye): 1 person, 4.00%
Retinal Oedema (swelling of retina): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Neovascularisation?

- Check whether Neovascularisation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Lucentis (25,647 reports)

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neovascularisation:

Neovascularisation (64 drugs)

Browse all the conditions that are associated with Neovascularisation:

Neovascularisation (87 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.